Clinical Trial

Phase Ib Clinical Study on the Efficacy and Safety of MDR-001 in Patients Who Are Obesity or Overweight

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 8, 2025 (before its estimated September 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a 12 weeks, multicenter, randomized, double-blind, placebo, parallel-controlled Phase Ib trail comparing the efficacy and safety of MDR-001 tablet versus placebo as an adjunct to a reduced calorie diet and increased physical activity in subjects with overweight or obesity, and to explore the optimal dose selection to support the subsequent Pivotal trial.
Trial Details
NCT Number NCT07110766
Lead Sponsor MindRank AI Ltd
Conditions Obesity & Overweight
Enrollment 24 participants
Start Date 2025-08-09
Primary Completion 2025-09-15 (estimated)
Study Completion 2025-10-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-08